Abstract: Cervical cancer is still the second most common malignancy in women worldwide.The high-risk HPV(human papilloma virus)has been found to be the main cause of the majority of cervical cancers and its precursor lesions.p53 tumor suppressor gene can inhibit cell proliferation and promote apoptosis effectively.Nearly half of human tumors are associated with mutation and inactivation of p53 gene p53 protein degradation by HPV E6 protein is a precondition for cervical cancers.To selectively kill the p53 function-losing tumor cells while protecting the normal cells and to develop HPV vaccines,and the combination using of medicines are the cervical cancer gene therapy goals for clinical immunologist.